Greg Parekh, PhD
Founder & Managing Partner
Greg Parekh is the founder and a Managing Partner of New Rhein. Before launching New Rhein, Greg led the integration planning for Alcon on behalf of Novartis AG, where he previously ran the Mergers & Acquisitions group from 2004 to 2009. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group from 1998 to 2004. Greg joined Deutsche Bank from Bear Stearns in New York, where he started his career in 1995 as an associate in the Life Sciences group.
Greg has served as a director of the companies in which New Rhein made it initial deal-by-deal investments, Novagali Pharma, SA (a Paris, France based ophthalmology company), Chase Pharmaceuticals, a U.S. Alzheimer’s drug company, and Biocartis NV, a Belgian oncology diagnostics company, for which Greg also served as Chief Executive Officer from 2011 to 2013. Greg presently serves on the boards of Fund 18 portfolio companies, Softhale NV and Neuraptive Therapeutics, Inc., Butterfly Medical Ltd. and is a director of Cancerlinq, a big-data digital healthcare platform and wholly owned subsidiary of the American Society of Clinical Oncology (ASCO). Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School and a dual-major B.A. from University of Rochester (magna cum laude). Greg's hobbies include gourmet cooking, downhill skiing and music.